Infectious Disease

The AJMC® Infectious Disease compendium is a comprehensive resource for news and interviews about the viruses, bacteria, fungi, and parasites that create illness and outbreaks.

Latest News

National Immunization Awareness Month. | Image Credit: design.designer - stock.adobe.com
5 Things Everyone Should Know for National Immunization Awareness Month

August 1st 2025

National Immunization Awareness Month highlights the importance of lifelong vaccination to prevent diseases, a practice that has averted millions of deaths, proven to be a cost-effective public health strategy, and offers crucial protection even to individuals who are immunocompromised.

Prenatal PFAS Exposure Alters Infant Vaccine-Related Immune Cells
Prenatal PFAS Exposure Alters Infant Vaccine-Related Immune Cells

August 1st 2025

Updated mRNA Vaccines Against JN.1 Show Strong Safety Signal in Real-World Data
Updated mRNA Vaccines Against JN.1 Show Strong Safety Signal in Real-World Data

July 31st 2025

Long COVID graphic | Image Credit: Parradee - stock.adobe.com
Long COVID More Common Among Socially Vulnerable Individuals

July 28th 2025

World Hepatitis Day graphic | Image Credit: uazzal - stock.adobe.com
Breaking Down Barriers to Hepatitis Elimination on World Hepatitis Day 2025

July 25th 2025

Advancing UTI Treatment: Highlights from IDWeek 2024

Discover groundbreaking research on urinary tract infections, including findings from the EAGLE-2 and EAGLE-3 trials. Learn how gepotidacin, a first-in-class oral therapy, addresses antimicrobial resistance and unmet needs in UTI management.

AJMC Post Conference Perspective logo
Continuing Medical Education
View All
August 13th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
August 13th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

Health care concept meaning Clostridium difficile Infection with phrase on the piece of paper: © Yurii Kibalnik - stock.adobe.com
April 12th 2023

Fecal Microbiota Therapy Potentially Cost-effective at Preventing Recurrent CDI

Jared Kaltwasser
The cost savings for health plans would increase if the therapy were used after the first recurrence of Clostridioides difficile infection (CDI).
Logo for What We're Reading
April 6th 2023

What We’re Reading: Medicare Advantage Changes; RSV Vaccine Effective; Brain Scans Show Obesity Differences

AJMC Staff
CMS finalizes plans to decrease overpayments to Medicare Advantage insurers; an experimental respiratory syncytial virus (RSV) vaccine is highly effective in infants when given to pregnant women; obesity may be influenced by different brain factors between men and women.
Jessica Allegretti, MD, MPH.
April 2nd 2023

Dr Jessica Allegretti Addresses Rebyota Utilization, Access Considerations for Recurrent CDI

Matthew Gavidia
Jessica Allegretti, MD, MPH, medical director of the Crohn's and Colitis Center, Brigham and Women's Hospital, speaks on current indications for Rebyota (fecal microbiota, live-jslm) in the treatment of recurrent Clostridioides difficile infection (CDI), as well as coverage and access-related implications for the drug.
World TB Day is March 24
March 24th 2023

World Tuberculosis Day: Easing the Continuum of Care Burden

John Parkinson
The Bill & Melinda Gates Medical Research Institute has multiple tuberculosis (TB) therapies and a prophylactic vaccine in development, and its chief medical officer, Michael W. Dunne, MD, remains optimistic long-term about the state of clinical care, especially in low-and-middle-income countries.
Jessica Allegretti, MD, MPH.
March 21st 2023

Dr Jessica Allegretti on Prevention and Treatment Strategies for Primary, Recurrent CDI

Matthew Gavidia
Jessica Allegretti, MD, MPH, medical director of the Crohn's and Colitis Center, Brigham and Women's Hospital, discusses the standard of care for the prevention and treatment of primary and recurrent Clostridioides difficile infection (CDI).
superbug infection
March 20th 2023

Dangerous Drug-Resistant Yeast Infection Rising Across the US, CDC Says

Allison Inserro
Candida auris was first reported in the United States in 2016; the highly contagious fungal infection has been labeled an “urgent threat” by the CDC, and its spread may have aided by underresourced public health systems.
What We’re Reading: North Dakota Supreme Court Blocks Abortion Ban; FDA Approve Paxlovid for COVID-19; Sanofi Announces $35 Insulin Price Cap
March 17th 2023

What We’re Reading: ND Supreme Court Blocks Abortion Ban; Paxlovid and COVID-19; Sanofi Joins Insulin Price Cuts

AJMC Staff
The high court in North Dakota voted to protect abortion in that state; an outside panel of FDA expert advisors voted to support a full approval for Paxlovid; Sanofi follows competitors' price caps for insulin.
doctor with clipboard.
March 16th 2023

FMT Demonstrates Safety, Efficacy for Treatment of Recurrent CDI in Patients With IBD

Matthew Gavidia
Risk of flare in patients with inflammatory bowel disease (IBD) was low after fecal microbiota transplantation (FMT) for the treatment of recurrent Clostridioides difficile infection (CDI).
Jessica Allegretti, MD, MPH.
March 11th 2023

Dr Jessica Allegretti Discusses Risk Factors, Burden of Disease for Clostridioides difficile infection

Matthew Gavidia
Jessica Allegretti, MD, MPH, medical director of the Crohn's and Colitis Center, Brigham and Women's Hospital, spoke on antibiotic use and other risk factors for the development of Clostridioides difficile infection.
Hospital room patient.
March 9th 2023

Newly Identified Metabolic Targets May Improve Treatment Strategies for CDI

Matthew Gavidia
Researchers from Brigham and Women’s Hospital and Massachusetts General Hospital identified new targets for small molecule drugs to counter Clostridioides difficile colonization and infection (CDI) in the gut and provide a new approach to rapidly define microbial metabolism for other applications.
Hospital bed.
March 2nd 2023

Evaluating Risk Factors for Clostridioides difficile Infection Among Hospitalized Patients With COVID-19

Matthew Gavidia
Incidence rates of health care-associated Clostridioides difficile infection were 3 times higher in patients with COVID-19 than those without coronavirus infection in a Serbian hospital.
Site Logo
February 21st 2023

Outcomes of Antiviral Treatment for Influenza in Type 2 Diabetes

Benjamin D. Lewing, PhD Christopher Wallick, PharmD Tu My To, PhD Henry Masters III, MD Parul Dayal, PhD Stephan W. Korom, MD Selina Tam, PharmD
Antiviral treatment was associated with lower health care resource utilization and costs in patients with type 2 diabetes and a diagnosis of influenza.
Hospitalized patient.
February 19th 2023

Gender, Department Linked With Length of Hospital Stay for Patients With Community-Acquired Infections

Matthew Gavidia
An increased risk of hospitalization for more than 6 days due to community-acquired infections was associated with male sex and admittance to the Pulmonology or Surgery department, with risk shown to differ according to pathogen.
People of different ethnicities.
February 14th 2023

USPSTF Advises Against Routine Serologic Screening for Genital Herpes Infection

Matthew Gavidia
The US Preventive Services Task Force (USPSTF) reaffirmed previous recommendations against routine serologic screening for genital herpes infection among asymptomatic adolescents and adults, including pregnant individuals.
Jessica Allegretti, MD, MPH.
February 9th 2023

Dr Jessica Allegretti on Cost-effectiveness Implications of Rebyota Approval for the Prevention of Recurrent CDI

Matthew Gavidia
Jessica Allegretti, MD, MPH, medical director of the Crohn's and Colitis Center, Brigham and Women's Hospital, discussed how the FDA’s approval of Rebyota for the prevention of recurrent Clostridioides difficile infection (CDI) may promote cost effective management of CDI for patients and health systems.
Black male patient.
February 7th 2023

Bloodstream Infection Risk Associated With Race, SES Among Patients on Hemodialysis

Matthew Gavidia
Data released in the CDC’s latest Morbidity and Mortality Weekly Report indicate that patients with end-stage kidney disease on hemodialysis who are Black, Hispanic/Latino, or of lower socioeconomic status (SES) are at greater risk of Staphylococcus aureus bloodstream infections, with Hispanic/Latino ethnicity cited as an independent risk factor.
Woman coughing.
February 4th 2023

Lower Risk of Severe COVID-19 Associated With Omicron vs Delta Variant

Matthew Gavidia
Vaccination was shown to lower risk of developing severe COVID-19 in both variants, with the largest difference in risk observed in patients aged 40 to 59 years.
What We’re Reading: HHS Updates Medicaid Managed Care; China’s COVID-19 Reporting; Public Health’s Immunization Messaging
January 5th 2023

What We’re Reading: HHS Updates Medicaid Policy; China Defends COVID-19 Reports; Public Health’s Immunization Messaging

AJMC Staff
HHS updated guidance for states using Medicaid managed care to manage nonmedical needs; anxieties surrounding new variants rise amidst underreported COVID-19 cases in China, which defended its counts; public health campaigns try new strategies to increase trust and promote immunizations.
What We’re Reading: China Hostile Over COVID-19 Testing; Biologics for Infectious Diseases; Congressional Report Blasts Biogen, FDA
January 3rd 2023

What We’re Reading: China Hostile Over COVID-19 Testing; Biologics for Infectious Diseases; Congressional Report Blasts Biogen, FDA

AJMC Staff
The Chinese government warns of backlash for countries requiring COVID-19 testing of travelers from China; monoclonal antibody drugs show some promise against infectious diseases, but costs need to be lower; the role of FDA and Biogen in approving Alzheimer drug Aduhelm is detailed in a scathing Congressional committee report.
Top 5 infectious disease articles.
December 26th 2022

Top 5 Most-Read Infectious Disease Articles of 2022

Matthew Gavidia
The top 5 most-read articles for infectious disease in 2022 explored preventive efforts and therapeutic innovations against Clostridioides difficile infections, as well as federal action on the COVID-19 pandemic.
Jessica Allegretti, MD, MPH.
December 21st 2022

Dr Jessica Allegretti Explains Rebyota’s Mechanism of Action for the Prevention of Recurrent CDI

Matthew Gavidia
Jessica Allegretti, MD, MPH, medical director of the Crohn's and Colitis Center, Brigham and Women's Hospital, explained the mechanism of action for Rebyota, the first fecal transplant therapy approved by the FDA for the prevention of recurrent Clostridioides difficile infection (CDI) in individuals 18 years and older, following antibiotic treatment for recurrent CDI.
Doctors.
December 16th 2022

ICYMI: Top Content From DDW 2022

Matthew Gavidia
Several therapeutic innovations in the management of Clostridioides difficile infection recurrence, current evidence on the efficacy of weight loss procedures in reversing nonalcoholic fatty liver disease, and an interview the use of artificial intelligence were spotlighted at Digestive Disease Week (DDW) 2022.
Doctor and patient.
December 12th 2022

DAA Therapy Linked With Improved Liver, Mortality Outcomes in Patients With Chronic Hepatitis C

Matthew Gavidia
Use of direct-acting antiviral (DAA) treatment (without interferon) was shown to reduce liver and nonliver complications, as well as improve long-term overall survival among patients with chronic hepatitis C.
Hospitalized patient.
December 6th 2022

COVID-19 Mortality Risk More Than Doubled Among Homeless Patients

Matthew Gavidia
A cross-sectional study showed that patients experiencing homelessness were at more than 2-fold greater age-adjusted mortality risk due to COVID-19 compared with the general population, with these increased risks observed across race/ethnicity and sex status.
Hospitalized patient.
December 6th 2022

Glucose-Lowering Drugs May Reduce Risk of COVID-19–Related Adverse Events in Patients With Diabetes

Matthew Gavidia
Patients with diabetes who reported use of sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, or metformin prior to COVID-19 infection were associated with lower COVID-19–related adverse outcomes during hospitalization.
Child vaccine.
December 3rd 2022

Gaps Remain in HPV Vaccine Coverage for Children Due to COVID-19 Pandemic

Matthew Gavidia
The monthly volume of human papillomavirus (HPV) vaccine doses administered have returned to the level observed prior to the COVID-19 pandemic among children in an integrated health care system in California, but HPV vaccine coverage remains lower compared with prepandemic levels.
FDA approved.
December 1st 2022

FDA Approves First Fecal Transplant Therapy for Prevention of CDI Recurrence

Matthew Gavidia
Ferring’s Rebyota, a novel first-in-class microbiota-based live biotherapeutic, has been approved by the FDA for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years and older, following antibiotic treatment for recurrent CDI.
Elderly patient.
November 23rd 2022

Nutrition Associated With Recurrent CDI Risk in Elderly Patients

Matthew Gavidia
Elderly Japanese patients with a high geriatric nutritional risk index (GNRI) were associated with significantly better Clostridioides difficile infection (CDI) relapse-free survival compared with those with low GNRI.
vaccine.
November 14th 2022

Examining Predictors of Vaccination Adherence for COVID-19, Influenza

Matthew Gavidia
Individuals who completed their full primary series of COVID-19 vaccination were more likely to report getting the influenza vaccine vs those who did not, and vice versa.
What We're Reading image
November 14th 2022

What We’re Reading: Alzheimer Drug Fails; Impact of Repeated COVID-19 Infection; Psychedelic Compounds Approved

AJMC Staff
Negative trial results come in for Roche’s experimental Alzheimer disease drug; high risks of several adverse outcomes seen with repeated SARS-CoV-2 infection; Colorado has passed a measure to legalize 2 psychedelic compounds for medicinal and recreational use.
<12345678910
...
12>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo